CRISPR-Cas systems function as adaptive immune systems by acquiring nucleotide sequences 18 called spacers that mediate sequence-specific defense against competitors. Uniquely, the 19 phage ICP1 encodes a Type I-F CRISPR-Cas system that is deployed to target and overcome 20 PLE, a mobile genetic element with anti-phage activity in Vibrio cholerae. Here, we exploit the 21 arms race between ICP1 and PLE to examine spacer acquisition and interference under 22 laboratory conditions to reconcile findings from wild populations. Natural ICP1 isolates encode 23 multiple spacers directed against PLE, but we find that single spacers do not equally interfere 24 with PLE mobilization. High-throughput sequencing to assay spacer acquisition reveals that 25 ICP1 can also acquire spacers that target the V. cholerae chromosome. We find that targeting 26 the V. cholerae chromosome proximal to PLE is sufficient to block PLE and propose a model in 27 which indirect chromosomal spacers are able to circumvent PLE by Cas2-3-mediated 28 processive degradation of the V. cholerae chromosome before PLE mobilization. Generally, 29 laboratory acquired spacers are much more diverse than the subset of spacers maintained by 30 ICP1 in nature, showing how evolutionary pressures can constrain CRISPR-Cas targeting in 31 ways that are often not appreciated through in vitro analyses. 32 33
Introduction 34
Phages often vastly outnumber their bacterial hosts in a variety of environments (1) . As 35 such, bacteria have evolved numerous mechanisms for phage defense, including adaptive 36 immunity via clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-37 associated (Cas) proteins (2,3). CRISPR-Cas systems are composed of a CRISPR array-a 38 series of "spacers" of foreign sequence alternating with repeats that are transcribed into 39 CRISPR RNAs (crRNAs)-and CRISPR-associated (Cas) genes. Together with crRNAs, Cas 40 proteins defend against foreign nucleic acids, such as the genome of an infecting phage, 41 through a three-step process: adaptation, crRNA expression, and interference. During 42 adaptation, a foreign DNA fragment is incorporated into the CRISPR array to provide a 43 molecular memory of the challenges that the host cell has faced. This CRISPR array is 44 expressed and processed into individual crRNAs, which complex with Cas proteins and survey 45 the cell for complementary invading nucleotides. Upon finding a complementary sequence, 46 termed protospacer, a Cas nuclease is recruited to the site to mediate interference by cleaving 47 the substrate, ultimately leading to the destruction of the invader (4,3). Across CRISPR-Cas 48 containing bacteria and archaea, Class 1 Type I CRISPR-Cas systems employing a Cas3 49 enzyme for DNA unwinding and degradation (5), are the most prevalent (6). 50 CRISPR-Cas systems do not discriminate between horizontally acquired traits based on 51 fitness gain or loss. Hence, CRISPR-Cas systems are equally capable of halting harmful 52 invading phage DNA as they are halting beneficial mobile genetic elements, including those 53 encoding antibiotic resistance and pathogenicity genes (7-9). As such, some pathogens only 54 have alternative anti-phage defense systems (10). For example, the currently circulating biotype 55 of epidemic Vibrio cholerae, the causative agent of the diarrheal disease cholera, does not rely 56 on CRISPR-Cas for phage defense (11). Instead, V. cholerae evolved to use phage inducible 57 chromosomal island-like elements (PLEs) to defend against the prevalent lytic phage, ICP1 58 (12). PLEs are mobile genetic elements that reside integrated in the small chromosome 59 (chromosome II) of V. cholerae (12) . During ICP1 infection of PLE(+) V. cholerae, PLE excises 60 from the host chromosome, replicates to high copy and is horizontally transduced to naïve 61 neighboring cells, all the while inhibiting phage replication through unknown mechanisms ( Fig.  62   1) . 63
In order to overcome the anti-phage activity encoded by V. cholerae PLE, some ICP1 64 isolates use a Type I-F CRISPR-Cas system that directly targets PLE ( Fig. 1) , making the 65 CRISPR-Cas system essential for the phage to form plaques on PLE(+) V. cholerae (13). Type 66 I-F systems are composed of three Csy proteins that make up the Csy complex along with 67 Cas6f, a protein involved in crRNA processing (14). This complex interacts with the processed 68 crRNA to search DNA for a complementary protospacer with an appropriate self versus non-self 69 discrimination sequence, known as the protospacer adjacent motif (PAM) (15). Upon finding a 70 match with an appropriate PAM, the trans-acting Cas2-3 fusion protein is recruited to degrade 71 the target DNA. In addition to exonuclease activity, Cas2-3 is a processive helicase in vitro, 72 allowing for continued degradation of the target DNA (16,17). Recently, sequence analysis 73 identified phages that are predicted to encode CRISPR arrays and/or Cas genes (18, 19) ; 74 however, ICP1 is the only phage shown to encode a fully functional CRISPR-Cas system 75 (12,13). 76
As is true when CRISPR-Cas is harnessed by a prokaryotic host for genome defense, 77 the ICP1-encoded CRISPR-Cas system is tasked with targeting and degrading a hostile mobile 78 genetic element. However, there are additional challenges associated with a phage encoding 79 and relying on CRISPR-Cas for its own survival. The ICP1 infection cycle occurs over a 20 80 minute period, and current data suggest that ICP1 synthesizes its CRISPR-Cas machinery de 81 novo upon infection of V. cholerae (13). PLE is induced to excise within minutes of infection 82 through interactions with an early phage-encoded gene product (20). Thus, in order to 83 overcome PLE, CRISPR synthesis and interference must outpace a rapidly replicating target. 84 ICP1 and V. cholerae are consistently co-isolated from patient stool samples in regions 85
where cholera is endemic such as Bangladesh (12, 21, 22 Here, we provide an up-to-date understanding of the genomic variants of ICP1 and PLE 94 circulating in Bangladesh. We find that natural ICP1 isolates encode multiple anti-PLE spacers 95 and experimentally validate that increased PLE targeting by ICP1 is required to fully abolish 96 PLE mobilization. Significantly, using a high-throughput spacer acquisition assay and 97 experimental validation, we show that noncanonical PAMs and indirect protospacers in the V. 98 cholerae small chromosome can unexpectedly provide protection against PLE. Our results 99 support a model in which ICP1-encoded CRISPR-Cas that is directed against the V. cholerae 100 small chromosome is in a race to reach PLE before it excises from the chromosome to exert its 101 anti-phage activity. Taken together, our study highlights the differences between interference 102 competent spacers under laboratory conditions and those that are selected for in nature to 103 provide mechanistic insight into the evolutionary pressures governing the interactions between 104 epidemic V. cholerae and its longstanding battle with the predatory phage ICP1. 105 106
Methods. 107

Strains, growth conditions and genomic analysis. 108
Phage, bacterial strains and plasmids used in this study are listed in Supplementary Tables 1-3 . 109
Bacteria were routinely grown at 37 C on lysogeny broth (LB) agar or in LB broth with aeration. 110
Media was supplemented with ampicillin (50 μg/ml), kanamycin (75 μg/ml), spectinomycin (100 111 μg/ml), and/or streptomycin (100 μg/ml) when appropriate. Phage susceptibility was determined 112 by standard soft agar overlays as described (11) and phage plaque spot plates were performed 113 as described previously (20 performed using the canu assembler v1.6 (24) to combine the PacBio and Oxford Nanopore 127 reads into genomic scaffolds for the large and small chromosomes using default settings and an 128 expected genome size of 4033460bp. This generated two scaffolds of the expected sizes for 129 each chromosome which were then polished with the Illumina paired-end sequences using Pilon 130 v1.22 (25) with the "fix all" command to generate a high-quality genomic assembly in a fasta 131 format of both chromosomes (Supplementary File 1). 132 V. cholerae mutants were constructed by natural transformation as described (26). 133
Mutations in ICP1 were generated using CRISPR-Cas mediated genome engineering with the 134 V. cholerae classical biotype Type I-E system as described (11) ( Supplementary Table 3 ). 135
Engineered phage +/-Cas1 D244A with a spacer 9 were validated by plaquing on a permissive 136 PLE 1 host and determining the frequency of phage with a newly acquired spacer by calculating 137 the efficiency of plaquing on the permissive PLE 1 host to a PLE 1 host with the protospacer 138 deleted. Examination of PLE replication and transduction during phage infection was described 139 as reported previously (12). 140 141
High throughput spacer acquisition, data processing and analyses 142
Three independent experiments were performed as follows: A 50 mL culture of PLE 1 V. 143
cholerae was grown to OD600 = 0.3 and infected with ICP1_2011_A S9 (13) at an MOI of 1. 144
Infected cells were incubated for 90 minutes at 37 C with aeration, at which point lysis was 145 observed. The lysate was treated with chloroform and centrifuged to remove bacterial debris. 146
Phage were precipitated with 10% (w/v) polyethylene glycol (PEG) 8000 at 4°C overnight. 147
Phage pellets were collected by centrifugation at 4°C and the passaging was repeated as 148 above. After three passages, the resulting pools were plated on the PLE 1 S8* host to select for 149 phage with expanded arrays that allow plaque formation. Phage DNA libraries were generated 150 by homopolymer tail-mediated PCR (HTM-PCR) as previously described (27). As ICP1_2011_A 151 possesses only a single functional CRISPR array ( Fig. 1b ), the expanded phage CRISPR 1 152 array was amplified from genomic DNA libraries by PCR using custom barcoded primers 153
( Supplementary Table 4 ) to sequence the leader proximal spacer. 50bp single-end sequencing 154 was performed on an Illumina HiSeq 2500 (Tufts University Core Facility) using a custom 155 sequencing primer. The resulting reads as fastq files (Supplementary File 2) were mapped to 156 the large and small chromosome of V. cholerae strain KDS1 using Bowtie v1.2.2 (28) with a 157 seed_length of 31 and allowing for 0 max_total_mismatches which ensured that spacer to 158 protospacer matches were 100% identical. These mappings were performed in two parallel 159 ways: first, to obtain all possible spacer mapping locations regardless of the number of identical 160 protospacer targets (i.e. translucent spacers in Fig 3b) and second, restricting max_alignments 161 to 1 which only mapped spacers with exactly one unique mapping location across both 162 chromosomes. With a custom Python script (https://git.io/fNVqZ) we extracted the PAM 163 sequences and GG PAM slippage locations from the restricted unique mappings. We also used 164 this script to generate spacer mapping location graphs for both set of mappings using 165
Biopython's GenomeDiagram module (29). 166
167
Results 168
ICP1-encoded CRISPR-Cas is fixed in the natural phage population 169
We set out to compare ICP1 and PLE from contemporary cholera patient stool samples 170 
Multiple spacers increase ICP1 CRISPR-Cas mediated PLE interference 188
All of the natural phage we isolated encode multiple CRISPR spacers against PLE ( Fig.  189 1b); however, previous work revealed that only one functional spacer is required for ICP1 to 190 overcome PLE-mediated anti-phage activity as evaluated by plaque formation (13). Conversely, 191 a single spacer against the PLE did not prevent transduction of PLE (12). To investigate the 192 consequences of varying spacer number and identity on PLE transduction and replication, we 193 used co-isolated ICP1 and PLE 1 V. cholerae obtained from a cholera patient sample in 2011 194 (13). This ICP1 isolate harbors two spacers (spacers 8 and 9) at the leading edge of the 195 CRISPR 1 array that target PLE 1. We also used an isogenic phage with a spontaneous loss of 196 spacer 9 (13), as well as one that acquired an additional 10 th spacer targeting PLE in vitro ( Fig. 2a ). Despite the ability to overcome PLE and form plaques, spacer 8 targeting was not sufficient 198 to decrease PLE transduction during ICP1 infection relative to an untargeted control ( Fig. 2b) . In 199 comparison, two anti-PLE spacers decreased PLE transduction during ICP1 infection and three 200 spacers completely abolished PLE transduction, showing that increased CRISPR targeting by 201 ICP1 has a stronger anti-PLE effect. To evaluate potential differences between spacer 8 and 202 spacer 9 on PLE targeting, we used PLE 1 with a protospacer mutation (PLE 1 PS8 *) that inhibits 203 spacer 8-mediated PLE targeting (13). Strikingly, just spacer 9 targeting PLE alone was able to 204 decrease PLE transduction to the same level as when two spacers were targeting PLE (Fig. 2b) . 205
We next analyzed the copy number of PLE during infection with the ICP1 encoding one 206 or two targeting spacers to identify if the differences in reducing PLE transduction were due to 207 differences in PLE copy number (Fig 2c) . In the absence of ICP1 CRISPR targeting, PLE 208
replicates to high copy number, which facilitates horizontal transmission. Targeting with only 209 one spacer was sufficient to significantly decrease PLE replication, and in agreement with the 210 transduction data, spacer 9 had a stronger inhibitory effect on PLE replication than spacer 8. 211
Altogether, these results demonstrate that not all spacers selected in nature equally interfere 212
with PLE mobilization and that increasing the number of spacers provides enhanced capacity of 213 ICP1 to interfere with PLE. 214 215
Interference-driven spacer acquisition in ICP1 reveals indirect targets and non-canonical 216
PAMs 217
Since spacer composition variability in nature was lower than we expected (Fig 1b) , we 218 next set out to experimentally sample the repertoire of spacers that ICP1 can acquire to 219 overcome PLE. Low-throughput experiments previously demonstrated that ICP1 can acquire 220 new spacers targeting the PLE under laboratory conditions without the need to overexpress cas 221 genes (13). To further analyze the natural process of interference-driven spacer acquisition in 222 this system, we performed high-throughput sequencing of expanded CRISPR arrays of phage 223 selected on PLE 1 V. cholerae. We infected PLE 1 V. cholerae with ICP1 containing spacer 8 224 (Fig 2a) , and the recovered lysate was probed for ICP1 progeny with newly acquired spacers 225 that allowed for plaque formation on a PLE 1 PS8* host. Illumina sequencing of the leader-226 proximal spacer in CRISPR 1 allowed us to sample over 10 6 acquired spacers in each replicate 227 experiment ( Supplementary Table 6 ). In order to accurately map the spacers to the PLE 1 V. 228 cholerae host, we performed complete whole-genome sequencing and assembly of the bacterial 229 genome ( Supplementary File 1) . As was previously reported (12), we found that PLE 1 was 230 integrated in a V. cholerae repeat (VCR), of which over 100 repeats intersperse the V. cholerae 231 small chromosome in a gene-capture region, the superintegron (30). In total, 96% of the 232 acquired spacers mapped to PLE, while, interestingly, the other 4% mapped to V. cholerae 233 chromosomes ( Supplementary Table 6 ). 234
Mapping of the spacers to the small chromosome showed a pattern of strand bias that 235 reflected previous observations in primed acquisition experiments performed in other Type I-F 236 systems (31), with a distribution of acquired spacers 5' of the protospacer on the non-targeted 237 strand and 3' of the protospacer on the targeted strand ( Fig. 3a, Supplementary Fig. 2) . The 238 distribution of spacers acquired 5' of the protospacer on the nontargeted were split between the 239 small chromosomal region proximal to the PLE 1 integration site (Fig. 3b) , as well as the 3' end 240 of PLE. Acquired spacers mapping to the V. cholerae chromosome were not evenly distributed 241 between the large and small chromosome, but instead ~90% of the chromosomal spacers 242 mapped to the small chromosome ( Supplementary Table 6, Fig. 3b ). Spacers that mapped to 243 the large chromosome were restricted to a mu-like region (Fig. 3c ), which was duplicated in this 244 strain and was also in the small chromosome proximal to PLE (Fig. 3b ). Acquired spacers 245 mapped uniformly throughout the superintegron, however, this is likely an artifact as the 246 superintegron is highly repetitive. When considering spacers that map to a single site in the 247 small chromosome, we observed an obvious bias for acquired spacers mapping closer to the 248 PLE integration site (Fig. 3b) . 249
Consistent with CRISPR + ICP1 isolates from nature ( Supplementary Figure 1) , the 250 majority (~70%) of the spacers acquired experimentally targeted protospacers in PLE 1 that 251 were flanked by a 3' GA PAM (Fig. 3d ). However, ~30% of protospacers in PLE had non-252 canonical PAMs, and of those, the majority were GG or GT. Previous CRISPR acquisition 253 studies in Type I-F systems indicate that alternative PAMs can be explained by a "slippage" 254 event (31,32). To identify putative slippage events, we analyzed the sequences adjacent to GG 255
PAMs and found that 45% of GG PAMs have a canonical GA within 3 nucleotides of the PAM 256 position, suggesting that the ICP1 acquisition machinery has a propensity to slip (Fig. 4a) . 257
We next wanted to determine if these non-canonical PAMs are functional for PLE 258 interference. To do so, we engineered ICP1 to encode a single spacer reflective of an 259 experimentally acquired spacer with the most common non-canonical PAMs: either a GG or GT 260 ( Fig. 3d ) and evaluated plaque formation on PLE 1 V. cholerae. Despite relying on a non-261 canonical PAM, we found that ICP1 is able to target those protospacers and overcome PLE, 262 albeit at a lower efficiency than when targeting a protospacer with a canonical GA PAM (Fig.  263   4b) . Even when no canonical PAM was within +/-3 nt, ICP1 was still able to overcome PLE 264 targeting a protospacer with a GT PAM. As PAM mutations are frequently a source for primed 265 acquisition (33), we tested if the observed residual CRISPR activity was due to further spacer 266 acquisition and interference. We constructed a Cas1 D244A mutation, which disrupts a 267 conserved metal coordinating residue to inhibit spacer acquisition (32) ( Supplementary Fig. 3 ) 268 and tested if plaque formation was altered (Fig 4b) . We observed no difference in the efficiency 269 of plaque formation between the Cas1 mutants and the parental phage, suggesting that the 270 ICP1 CRISPR-Cas system is more tolerant of divergent PAMs during infection than previously 271 characterized (13). 272 273
Protospacers in the small chromosome facilitate ICP1 CRISPR-Cas-mediated PLE 274
interference In our spacer acquisition experiment we identified a subset of spacers that target a mu-276 like region in the V. cholerae large chromosome (Fig. 3c ), suggesting that CRISPR targeting of 277 the mu-like region was advantageous in overcoming PLE. To test the role of the mu-like region 278 protospacer in PLE interference, we isolated ICP1 that had acquired a spacer that targets the 279 mu-like region and was able to form plaques on PLE 1 PS8* (Fig 5a) . Since assembly of the V. 280 cholerae genome revealed that the mu-like region was present in each chromosome (Fig 5a) we 281 wanted to evaluate if targeting the mu-like region per se was allowing for plaque formation, or if 282 the chromosomal context was important in allowing for CRISPR-meditated interference with 283 PLE. To test this difference, we generated a single knockout of the mu-like region in the large 284 chromosome and a double knockout in both chromosomes. ICP1 CRISPR-mediated 285 interference with PLE was abolished in the double knockout, however, knocking out the mu-like 286 region in the large chromosome had no effect on ICP1 plaque formation (Fig 5b) . These results 287
show that CRISPR targeting of the V. cholerae large chromosome is dispensable for phage 288 overcoming PLE, while targeting the small chromosome is sufficient to overcome PLE activity. 289 290
When CRISPR goes off target: going the distance to maintain interference 291
As processivity of Cas2-3 has been demonstrated in vitro (17), we speculated that ICP1 292 targeting of the small chromosome proximal to PLE interferes with PLE anti-phage activity by 293 the processive degradation of PLE along with the chromosome; however, PLE excises from the 294 chromosome early during ICP1 infection (20). This timing suggests that CRISPR targeting and 295
Cas2-3 processive degradation of the small chromosome would have to happen prior to PLE 296 excision and would therefore likely be distance dependent. In support of this hypothesis, 297 experimentally acquired spacers mapping to the small chromosomal clustered proximal to PLE 298 ( Fig. 3b) . To test the impact of targeting at increasing distances from PLE, we engineered ICP1 299 to possess CRISPR arrays containing only one spacer drawn from the experimental acquisition 300 pool that targets the small chromosome at varying distances away from PLE. We then assayed the ability of these engineered phage to overcome PLE and form plaques (Fig. 6a) . As a 302 positive control, ICP1 engineered with a spacer that targets internal to PLE formed robust and 303 equal plaques on PLE(-) and PLE 1 hosts. In comparison, phage with a spacer that targets far 304 (>400 kb) from PLE were unable to form plaques on PLE 1. Conversely, ICP1 that target a 305 protospacer only 0.5, 1.5 or 2.5 kb from PLE were able to efficiently overcome PLE and form 306 plaques. Phage targeting protospacers at intermediate distances away from PLE (>20 kb) 307 demonstrated weak plaque formation on PLE 1. Surprisingly, we observed that ICP1 with some 308 spacers targeting relatively far from PLE (53 and 46kb away) were still able to form robust 309 plaques on PLE 1 (Fig 6a) . While all of the spacers selected for this assay had one perfect 310 protospacer match in the chromosome (and have a GA PAM), we identified >100 putative 311 promiscuous target sites for these spacers which would bring the chromosomal target much 312 closer to PLE 1, which may explain these phage's ability to overcome PLE. To test if spacer 313 acquisition had a role in plaque formation, we engineered Cas1 deficient ICP1 in each CRISPR 314 proficient chromosomal targeting phage and assayed for plaque formation on the PLE 1 host. 315
Despite being unable to acquire spacers ( Supplementary Fig. 3) , the phage retained the same 316 plaquing phenotype. We quantified the weaker plaque formation observed when ICP1 targets 317 >20 kb away from PLE 1 by measuring plaque size compared to PLE (-) V. cholerae (Fig 6b) . 318
As compared to phage with PLE internal and PLE proximal spacers, phage with chromosomal 319 spacers targeting >20 kb away from PLE had significantly limited plaque size. These results 320 indicate that some PLE-mediated anti-phage activity is retained when CRISPR-Cas is directed 321 at increasing distances from PLE in the small chromosome. 322
To control for differences in spacer sequences, we also varied the location of the PLE 323 and tested the ability of ICP1 with a single chromosomal spacer targeting the small 324 chromosome to interfere with PLE 1. Following ICP1-mediated transduction, PLE 1 integrates 325 into the V. cholerae repeat (VCR) of the new host (12). We collected a pool of PLE 1 326 transductants where PLE was integrated at varying distances from the chromosomal 327 protospacer and challenged these strains with ICP1. As a control, we determined that all of the 328 tested PLE 1 V. cholerae hosts were susceptible to ICP1 CRISPR-Cas interference when ICP1 329 possessed a PLE internal spacer ( Supplementary Fig. 4) ; consistent with our earlier finding, 330 PLE integrated at an increasing distance away from the protospacer was less susceptible to 331 ICP1-encoded CRISPR interference (Fig. 6c) . 332 333
Discussion 334
Our results reveal that the latest front in the ongoing arms race between contemporary 335 isolates of epidemic V. cholerae and its predator ICP1 necessitate the persistence of the ICP1-336 encoded Type I-F CRISPR-Cas system to counter PLE-mediated anti-phage activity (Fig 1) . By 337 using a high-throughput spacer acquisition assay, we gained insight into the full range of 338 spacers that can combat PLE. Interestingly, our experimental findings on acquisition and 339 interference do not reflect the rather limited diversity of spacers that ICP1 maintains against 340 PLE in nature. These results highlight that not all spacers are equally proficient for interference, 341
and that coupled analysis of these competing mobile genetic elements from nature reveals the 342 evolutionary benefits of a particular complement of spacers more so than laboratory-based 343 studies. Despite a lack of clear evidence indicating where the ICP1-encoded CRISPR-Cas 344 system originated, it serves as a tractable model through which we can examine the biology of 345 an endogenous Type I-F CRISPR-Cas system against its cognate foe. 346
Co-culture studies competing phage against CRISPR-Cas proficient bacterial hosts 347 demonstrated that mutational escape by phage is limited by bacterial populations that have 348 heterogenous CRISPR arrays (34). Here, we see that PLE 1 is highly conserved over time, 349 even when co-circulating with CRISPR proficient ICP1. In light of previous suggestions, the 350 diversity of CRISPR arrays in ICP1 populations may limit the success of PLE escape mutants. 351
Surprisingly, however, we see very little diversity in the spacer composition of ICP1 CRISPR 352 arrays with the same minimal spacers being conserved in phage circulating for over eight years 353 ( Fig. 1b) . Likewise, CRISPR-proficient ICP1 isolated from nature always encoded more than 354 one spacer against PLE, which would be expected to limit CRISPR escape mutations. It may be 355 that there is limited room for genetic drift in the PLE genome, permitting ICP1 to streamline its 356 CRISPR array, keeping only the most efficient spacers while also maintaining an advantageous 357 genome size. 358
Akin to studies of bacterial Type I-F CRISPR-Cas mediated interference with plasmid 359 transformation and conjugation (35), we similarly see that the spacer sequence and quantity of 360 spacers in the array have a role in ICP1's ability to abolish PLE spread (Fig. 2) . This may be 361 due to differences in crRNA abundance or stability, or sequence dependent subtleties that 362 dictate interference potential, as has been proposed previously (36). Despite spacer 9's 363 improved interference with PLE mobilization compared to spacer 8, we still observed a slight 364 defect in plaque size when comparing engineered phage with only spacer 9 relative to a PLE(-) 365 host ( Fig. 6b ), suggesting that even this improved spacer alone is not sufficient to fully 366 overcome PLE-mediated anti-phage activity. By encoding a seemingly redundant set of spacers 367 targeting PLE, ICP1 increases its ability to overcome PLE and limit PLE spread in the 368
environment. 369
As expected, the majority of spacers acquired in our high-throughput acquisition assay 370 directly target PLE (Fig. 3a) . Analysis of natural ICP1 isolates recovered from cholera patient 371 stool samples shows that the phage-encoded CRISPR-Cas system recognizes a GA PAM, 372
( Supplementary Fig. 1 ) which, although atypical for Type I-F systems (37), has been confirmed 373 through single mutations to a C in both positions (13). Notably, we found that ICP1 was able to 374 incorporate spacers that targeted non-canonical PAMs (Fig. 3d ) and that these spacers can 375 suffice for PLE interference (Fig. 4b) . In comparison to another high throughput spacer 376 acquisition assay in a Type I-F system, which found >90% of all protospacers flanked by the 377 canonical PAM (31), it appears that the phage-encoded system is less discriminating with only 378 70% of protospacers flanked by the expected PAM. However, targeting a protospacer with a 379 non-canonical PAM reduced the efficiency of plaquing compared to the canonical PAM (Fig 4b) . 380
As such, in nature ICP1 targeting a protospacer with a non-canonical PAM would not be able to 381 completely interfere with PLE and thus would be selected against. This hypothesis is 382 additionally supported by the observation that very few non-canonical PAM protospacers were 383 associated with indirect targets in the small chromosome. As these chromosomal spacers are 384 themselves less proficient for interference ( Fig. 6a and 6b) , the added disadvantage of targeting 385 a protospacer with a non-canonical PAM likely tips the balance in favor of PLE, likely explaining 386 the lower abundance of these spacers in our selection experiments. 387
Despite the presence of spacers that target the V. cholerae large chromosome in the 388 high-throughput spacer acquisition assay (Fig. 3c ), we show that targeting this chromosome is 389 dispensable for CRISPR interference of PLE (Fig. 5b) . Interestingly, two of the natural ICP1 390
isolates contain a spacer that targets a gene on the V. cholerae large chromosome (Fig. 1b) . 391
We speculate that this spacer was acquired from a V. cholerae strain possessing a duplication 392 or rearrangement that is not represented in currently sequenced isolates, in which the 393 protospacer was in the small chromosome proximal to PLE, allowing the phage to overcome 394 PLE activity. However, this spacer does not seem to be maintained in the phage population, 395 likely due to diminished PLE interference relative to PLE-direct spacers as we experimentally 396 observed. 397 CRISPR targeting of the V. cholerae small chromosome can overcome PLE, but our 398 results suggest a model in which there is a limit to the distance over which processive Cas2-3 399 degradation can occur to reach the PLE prior to excision (Fig. 6d) , an action which occurs within 400 five minutes of ICP1 infection that is directed by an early-expressed ICP1 protein (20). The limit 401 of processivity appears to be around a distance of 23 kb ( Fig. 6a and 6c ), at which point either 402
Cas2-3 is unable to continue to process along the V. cholerae chromosome or PLE excises 403 before interference occurs. In vitro studies of Cas3 from Type I-E systems have demonstrated 404
Cas3 translocation velocities of 89 to 300 bases per second and average processivities 405 between 12 to 19 kb (38,39), however, the functional role and limitations of processivity in vivo 406 are not known. Our results are the first indications of Cas2-3 processivity in vivo, with over 22 kb 407 from a distal chromosomal protospacer over which CRISPR-Cas can maintain activity to 408 overcome PLE. As this event must occur within five minutes of ICP1 initiating infection, the 409 estimated processivity of ICP1 Cas2-3 is within the range of what has been reported for Type I-410 E Cas3, which is especially remarkable given the complexity of the crowded intracellular 411 environment compared to simplified in vitro systems. 412
In comparison to other Cas nucleases like Cas9, which introduces a single double-413 stranded break (40,41), Cas2-3 degrades DNA as it translocates away from the protospacer 414 (17), making it more likely to destroy and thus interfere with its target. This predicted advantage 415 may account for the increased prevalence of Type I systems for phage defense (42). In the 416 context of the battle between ICP1 and PLE, this processivity permits interference even with an 417 indirect CRISPR target and has important implications for harnessing CRISPR-Cas in 418 biotechnology and medicine. Since the characterization of the ICP1-encoded CRISPR-Cas 
